{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:47:44Z","timestamp":1789469264486,"version":"build-2803163510"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA262815"],"award-info":[{"award-number":["CA262815"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["EB029122"],"award-info":[{"award-number":["EB029122"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["GM140929"],"award-info":[{"award-number":["GM140929"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HD107206"],"award-info":[{"award-number":["HD107206"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved clinical success, but remains limited in solid tumors by antigen escape and tumor heterogeneity. Here, we engineer a high-affinity R-phycoerythrin (PE)-binding monobody to create a PE-programmable CAR toward user-defined antigens sequentially or simultaneously. To reduce off-tumor toxicity, we implement a drug-gated light-activation approach (DGLA) strategy to spatially confine CAR function. We further couple DGLA-controlled tumor antigen presentation with synNotch-mediated programmable antigen-targeting CAR (sPAT) to establish programmable CAR-antigen pairing (DGLA-sPAT). This system induces clinically validated antigens on tumor cells as local \u2018training centers\u2019 that recruit and activate sPAT CAR T cells, enabling elimination of entire tumor populations through broadly expressed tumor antigens using PE-conjugated antibodies. In vivo, DGLA-sPAT manifests local T cell activation and potent tumor suppression with minimal off-tumor toxicity. Thus DGLA-sPAT provides a modular and spatially controlled framework to overcome antigen escape and heterogeneity while improving safety in solid-tumor CAR-T therapy.<\/jats:p>","DOI":"10.1038\/s41467-026-70855-9","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:23:12Z","timestamp":1773958992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineering programmable CAR and antigen pairing via drug-gated light activation"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-3300","authenticated-orcid":false,"given":"Ziliang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praopim","family":"Limsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6313-6015","authenticated-orcid":false,"given":"Yiqian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianze","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuohang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linshan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly E.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-9066","authenticated-orcid":false,"given":"Longwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0265-326X","authenticated-orcid":false,"given":"Yingxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"70855_CR1","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817\u20134828 (2011).","journal-title":"Blood"},{"key":"70855_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"70855_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.2591","volume":"37","author":"D Sermer","year":"2019","unstructured":"Sermer, D. & Brentjens, R. CAR T-cell therapy: full speed ahead. Hematol. Oncol. 37, 95\u2013100 (2019).","journal-title":"Hematol. Oncol."},{"key":"70855_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"70855_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378, eaba1624 (2022).","journal-title":"Science"},{"key":"70855_CR6","doi-asserted-by":"crossref","unstructured":"Choe, J. H. et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci. Transl. Med. 13, eabe7378 (2021).","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"70855_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167, 419\u2013432.e416 (2016).","journal-title":"Cell"},{"key":"70855_CR8","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1021\/acssynbio.1c00007","volume":"10","author":"YJ Cao","year":"2021","unstructured":"Cao, Y. J. et al. Switchable CAR-T cells outperformed traditional antibody-redirected therapeutics targeting breast cancers. ACS Synth. Biol. 10, 1176\u20131183 (2021).","journal-title":"ACS Synth. Biol."},{"key":"70855_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi, F. et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res. Ther. 12, 81 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"70855_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","volume":"14","author":"J Edeline","year":"2021","unstructured":"Edeline, J., Houot, R., Marabelle, A. & Alcantara, M. CAR-T cells and BiTEs in solid tumors: challenges and perspectives. J. Hematol. Oncol. 14, 65 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"70855_CR11","doi-asserted-by":"crossref","unstructured":"Schoutrop, E. et al. Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models. J. Immunother. Cancer 11, e005691 (2023).","DOI":"10.1136\/jitc-2022-005691"},{"key":"70855_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1141","volume":"12","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Engineering chimeric antigen receptor T cells for solid tumour therapy. Clin. Transl. Med. 12, e1141 (2022).","journal-title":"Clin. Transl. Med."},{"key":"70855_CR13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"70855_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han, X., Wang, Y., Wei, J. & Han, W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J. Hematol. Oncol. 12, 128 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"70855_CR15","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J. Clin. Investig. 126, 3036\u20133052 (2016).","journal-title":"J. Clin. Investig."},{"key":"70855_CR16","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.7150\/ijbs.63181","volume":"17","author":"Z Liang","year":"2021","unstructured":"Liang, Z. et al. Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer. Int. J. Biol. Sci. 17, 4365\u20134376 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"70855_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah, E., Lin, M. Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. 4, 498\u2013508 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"70855_CR18","doi-asserted-by":"publisher","first-page":"2386187","DOI":"10.1155\/2018\/2386187","volume":"2018","author":"S Sun","year":"2018","unstructured":"Sun, S., Hao, H., Yang, G., Zhang, Y. & Fu, Y. Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies. J. Immunol. Res. 2018, 2386187 (2018).","journal-title":"J. Immunol. Res"},{"key":"70855_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","volume":"5","author":"D Schneider","year":"2017","unstructured":"Schneider, D. et al. A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J. Immunother. Cancer 5, 42 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"70855_CR20","doi-asserted-by":"crossref","unstructured":"Castellarin, M. et al. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. JCI Insight 5, e136012 (2020).","DOI":"10.1172\/jci.insight.136012"},{"key":"70855_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay9209","volume":"6","author":"Z Huang","year":"2020","unstructured":"Huang, Z. et al. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci. Adv. 6, eaay9209 (2020).","journal-title":"Sci. Adv."},{"key":"70855_CR22","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41551-021-00779-w","volume":"5","author":"Y Wu","year":"2021","unstructured":"Wu, Y. et al. Control of the activity of CAR-T cells within tumours via focused ultrasound. Nat. Biomed. Eng. 5, 1336\u20131347 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"70855_CR23","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","volume":"350","author":"CY Wu","year":"2015","unstructured":"Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J. & Lim, W. A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350, aab4077 (2015).","journal-title":"Science"},{"key":"70855_CR24","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426\u20131438.e1411 (2018).","journal-title":"Cell"},{"key":"70855_CR25","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers, D. T. et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc. Natl. Acad. Sci. 113, E459\u2013E468 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"70855_CR26","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1073\/pnas.1524193113","volume":"113","author":"JS Ma","year":"2016","unstructured":"Ma, J. S. et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc. Natl. Acad. Sci. 113, E450\u2013E458 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"70855_CR27","doi-asserted-by":"crossref","unstructured":"Schneider, D. et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci. Transl. Med. 13, eabc6401 (2021).","DOI":"10.1126\/scitranslmed.abc6401"},{"key":"70855_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/elps.1150140115","volume":"14","author":"K Nakamura","year":"1993","unstructured":"Nakamura, K., Mimura, Y. & Takeo, K. Immune response to a hapten of fluorescein isothiocyanate in a single mouse analyzed by two-dimensional affinity electrophoresis. Electrophoresis 14, 81\u201387 (1993).","journal-title":"Electrophoresis"},{"key":"70855_CR29","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/elps.1150190848","volume":"19","author":"P Wang","year":"1998","unstructured":"Wang, P. & Nakamura, K. Effects of carrier and hapten array on the production of anti-hapten antibodies analyzed by two-dimensional affinity electrophoresis. Electrophoresis 19, 1506\u20131510 (1998).","journal-title":"Electrophoresis"},{"key":"70855_CR30","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/intimm\/dxm080","volume":"19","author":"T Shimizu","year":"2007","unstructured":"Shimizu, T. et al. T cells specific to hapten carrier but not to carrier alone assist in the production of anti-hapten and anti-carrier antibodies. Int Immunol. 19, 1157\u20131164 (2007).","journal-title":"Int Immunol."},{"key":"70855_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41587-021-01036-w","volume":"40","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. A small and highly sensitive red\/far-red optogenetic switch for applications in mammals. Nat. Biotechnol. 40, 262\u2013272 (2022).","journal-title":"Nat. Biotechnol."},{"key":"70855_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20671-6","volume":"12","author":"S Park","year":"2021","unstructured":"Park, S. et al. Direct control of CAR T cells through small molecule-regulated antibodies. Nat. Commun. 12, 710 (2021).","journal-title":"Nat. Commun."},{"key":"70855_CR33","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41565-021-00982-5","volume":"16","author":"NT Nguyen","year":"2021","unstructured":"Nguyen, N. T. et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat. Nanotechnol. 16, 1424\u20131434 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"70855_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202100722","volume":"17","author":"A Kobayashi","year":"2022","unstructured":"Kobayashi, A. et al. Light-controllable binary switch activation of CAR T cells. ChemMedChem 17, e202100722 (2022).","journal-title":"ChemMedChem"},{"key":"70855_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.chembiol.2018.01.002","volume":"25","author":"P Limsakul","year":"2018","unstructured":"Limsakul, P. et al. Directed evolution to engineer monobody for FRET biosensor assembly and imaging at live-cell surface. Cell Chem. Biol. 25, 370\u2013379.e374 (2018).","journal-title":"Cell Chem. Biol."},{"key":"70855_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4067\/S0716-97602013000100013","volume":"46","author":"Q Pan","year":"2013","unstructured":"Pan, Q. et al. Antitumor function and mechanism of phycoerythrin from Porphyra haitanensis. Biol. Res. 46, 87\u201395 (2013).","journal-title":"Biol. Res"},{"key":"70855_CR37","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.3390\/md13085358","volume":"13","author":"RE Cian","year":"2015","unstructured":"Cian, R. E., Drago, S. R., de Medina, F. S. & Mart\u00ednez-Augustin, O. Proteins and carbohydrates from red seaweeds: evidence for beneficial effects on gut function and microbiota. Mar. Drugs 13, 5358\u20135383 (2015).","journal-title":"Mar. Drugs"},{"key":"70855_CR38","doi-asserted-by":"crossref","unstructured":"Rosa, G. P. et al. Seaweed secondary metabolites with beneficial health effects: an overview of successes in in vivo studies and clinical trials. Mar. Drugs 18, 8 (2019).","DOI":"10.3390\/md18010008"},{"key":"70855_CR39","doi-asserted-by":"publisher","first-page":"w14545","DOI":"10.4414\/smw.2017.14545","volume":"147","author":"O Hantschel","year":"2017","unstructured":"Hantschel, O. Monobodies as possible next-generation protein therapeutics - a perspective. Swiss Med. Wkly 147, w14545 (2017).","journal-title":"Swiss Med. Wkly"},{"key":"70855_CR40","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/febs.15515","volume":"288","author":"S Muyldermans","year":"2021","unstructured":"Muyldermans, S. A guide to: generation and design of nanobodies. FEBS J. 288, 2084\u20132102 (2021).","journal-title":"FEBS J."},{"key":"70855_CR41","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1021\/acssynbio.9b00175","volume":"8","author":"ME Allen","year":"2019","unstructured":"Allen, M. E. et al. An AND-gated drug and photoactivatable Cre-loxP system for spatiotemporal control in cell-based therapeutics. ACS Synth. Biol. 8, 2359\u20132371 (2019).","journal-title":"ACS Synth. Biol."},{"key":"70855_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nchembio.2063","volume":"12","author":"A Taslimi","year":"2016","unstructured":"Taslimi, A. et al. Optimized second-generation CRY2-CIB dimerizers and photoactivatable Cre recombinase. Nat. Chem. Biol. 12, 425\u2013430 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"70855_CR43","doi-asserted-by":"publisher","DOI":"10.1063\/5.0073746","volume":"6","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Engineering CAR T cells for enhanced efficacy and safety. APL Bioeng. 6, 011502 (2022).","journal-title":"APL Bioeng."},{"key":"70855_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 31\u201346 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70855_CR45","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp, M. S. et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134\u20134140 (2014).","journal-title":"J. Clin. Oncol."},{"key":"70855_CR46","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","volume":"126","author":"G Zugmaier","year":"2015","unstructured":"Zugmaier, G. et al. Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood 126, 2578\u20132584 (2015).","journal-title":"Blood"},{"key":"70855_CR47","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella, M. & Maus, M. V. Catch me if you can: leukemia Escape after CD19-directed T cell immunotherapies. Comput Struct. Biotechnol. J. 14, 357\u2013362 (2016).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"70855_CR48","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","volume":"21","author":"S Daya","year":"2008","unstructured":"Daya, S. & Berns, K. I. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 21, 583\u2013593 (2008).","journal-title":"Clin. Microbiol. Rev."},{"key":"70855_CR49","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","volume":"164","author":"L Morsut","year":"2016","unstructured":"Morsut, L. et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164, 780\u2013791 (2016).","journal-title":"Cell"},{"key":"70855_CR50","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf, E. A. et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2, 361\u2013370 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"70855_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30102-3","volume":"13","author":"M Milani","year":"2022","unstructured":"Milani, M. et al. Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates. Nat. Commun. 13, 2454 (2022).","journal-title":"Nat. Commun."},{"key":"70855_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54477-7","volume":"15","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Ultrasound control of genomic regulatory toolboxes for cancer immunotherapy. Nat. Commun. 15, 10444 (2024).","journal-title":"Nat. Commun."},{"key":"70855_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat. Rev. Clin. Oncol. 20, 49\u201362 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70855_CR54","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41392-025-02178-y","volume":"10","author":"J Nie","year":"2025","unstructured":"Nie, J. et al. Deep insight into cytokine storm: from pathogenesis to treatment. Signal Transduct. Target. Ther. 10, 112 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"70855_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","volume":"30","author":"S Gill","year":"2016","unstructured":"Gill, S., Maus, M. V. & Porter, D. L. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 30, 157\u2013167 (2016).","journal-title":"Blood Rev."},{"key":"70855_CR56","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1182\/blood.V126.23.5432.5432","volume":"126","author":"M Castellarin","year":"2015","unstructured":"Castellarin, M. et al. A novel small animal model to test on-target off-tumor cytoxicity of adoptive immune therapies. Blood 126, 5432 (2015).","journal-title":"Blood"},{"key":"70855_CR57","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1021\/acssynbio.8b00512","volume":"8","author":"D Chakravarti","year":"2019","unstructured":"Chakravarti, D., Caraballo, L. D., Weinberg, B. H. & Wong, W. W. Inducible gene switches with memory in human T cells for cellular immunotherapy. ACS Synth. Biol. 8, 1744\u20131754 (2019).","journal-title":"ACS Synth. Biol."},{"key":"70855_CR58","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"70855_CR59","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"70855_CR60","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","volume":"31","author":"AR Haas","year":"2023","unstructured":"Haas, A. R. et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol. Ther. 31, 2309\u20132325 (2023).","journal-title":"Mol. Ther."},{"key":"70855_CR61","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","volume":"40","author":"HS Li","year":"2022","unstructured":"Li, H. S. et al. High-performance multiplex drug-gated CAR circuits. Cancer Cell 40, 1294\u20131305.e1294 (2022).","journal-title":"Cancer Cell"},{"key":"70855_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12800-7","volume":"10","author":"BH Weinberg","year":"2019","unstructured":"Weinberg, B. H. et al. High-performance chemical- and light-inducible recombinases in mammalian cells and mice. Nat. Commun. 10, 4845 (2019).","journal-title":"Nat. Commun."},{"key":"70855_CR63","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.coi.2018.03.002","volume":"51","author":"N Chen","year":"2018","unstructured":"Chen, N., Li, X., Chintala, N. K., Tano, Z. E. & Adusumilli, P. S. Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr. Opin. Immunol. 51, 103\u2013110 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"70855_CR64","doi-asserted-by":"crossref","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"70855_CR65","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai, H. et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J. Hematol. Oncol. 13, 30 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"70855_CR66","doi-asserted-by":"crossref","unstructured":"Larson, S. M. et al. CD19\/CD20 bispecific chimeric antigen receptor (CAR) in na\u00efve\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma. Cancer Discov. 13, 580\u2013597 (2022).","DOI":"10.1158\/2159-8290.CD-22-0964"},{"key":"70855_CR67","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina, A. & Maher, J. Strategies to address chimeric antigen receptor tonic signaling. Mol. Cancer Ther. 17, 1795\u20131815 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"70855_CR68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2219086120","volume":"120","author":"C Lamarche","year":"2023","unstructured":"Lamarche, C. et al. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion. Proc. Natl. Acad. Sci. 120, e2219086120 (2023).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"70855_CR69","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res. 33, 341\u2013354 (2023).","journal-title":"Cell Res."},{"key":"70855_CR70","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021).","journal-title":"Science"},{"key":"70855_CR71","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","volume":"185","author":"I Zhu","year":"2022","unstructured":"Zhu, I. et al. Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell 185, 1431\u20131443.e1416 (2022).","journal-title":"Cell"},{"key":"70855_CR72","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","volume":"18","author":"K Tamada","year":"2012","unstructured":"Tamada, K. et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin. Cancer Res. 18, 6436\u20136445 (2012).","journal-title":"Clin. Cancer Res."},{"key":"70855_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2889","volume":"13","author":"DL Holliday","year":"2011","unstructured":"Holliday, D. L. & Speirs, V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 13, 215 (2011).","journal-title":"Breast Cancer Res."},{"key":"70855_CR74","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"70855_CR75","first-page":"677","volume":"27","author":"M Movahedin","year":"2017","unstructured":"Movahedin, M. et al. Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen. Glycobiology 27, 677\u2013687 (2017).","journal-title":"Glycobiology"},{"key":"70855_CR76","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1023\/A:1011379725811","volume":"6","author":"SJ Gendler","year":"2001","unstructured":"Gendler, S. J. MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia 6, 339\u2013353 (2001).","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"70855_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.exer.2018.09.003","volume":"178","author":"MP Simunovic","year":"2019","unstructured":"Simunovic, M. P. et al. Optogenetic approaches to vision restoration. Exp. Eye Res. 178, 15\u201326 (2019).","journal-title":"Exp. Eye Res."},{"key":"70855_CR78","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.2147\/OPTH.S370032","volume":"16","author":"N Cross","year":"2022","unstructured":"Cross, N., van Steen, C., Zegaoui, Y., Satherley, A. & Angelillo, L. Current and future treatment of retinitis pigmentosa. Clin. Ophthalmol. 16, 2909\u20132921 (2022).","journal-title":"Clin. Ophthalmol."},{"key":"70855_CR79","doi-asserted-by":"crossref","unstructured":"Kamar, S. et al. Degenerated cones in cultured human retinas can successfully be optogenetically reactivated. Int. J. Mol. Sci. 21, 522 (2020).","DOI":"10.3390\/ijms21020522"},{"key":"70855_CR80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/OAJCT.S259702","volume":"2020","author":"M White","year":"2020","unstructured":"White, M., Mackay, M. & Whittaker, R. Taking optogenetics into the human brain: opportunities and challenges in clinical trial design. Open Access J. Clin. Trials 2020, 33\u201341 (2020).","journal-title":"Open Access J. Clin. Trials"},{"key":"70855_CR81","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jmb.2020.03.015","volume":"432","author":"Z Huang","year":"2020","unstructured":"Huang, Z., Ouyang, M., Lu, S., Wang, Y. & Peng, Q. Optogenetic control for investigating subcellular localization of Fyn kinase activity in single live cells. J. Mol. Biol. 432, 1901\u20131909 (2020).","journal-title":"J. Mol. Biol."},{"key":"70855_CR82","doi-asserted-by":"crossref","unstructured":"O\u2019Donoghue, G. P. et al. T cells selectively filter oscillatory signals on the minutes timescale. Proc. Natl. Acad. Sci. 118, e2019285118 (2021).","DOI":"10.1073\/pnas.2019285118"},{"key":"70855_CR83","doi-asserted-by":"crossref","unstructured":"Limsakul, P. et al. Immunomodulatory Effects of Curcumin on CAR T-Cell Therapy. Antioxidants 14, 454 (2025).","DOI":"10.3390\/antiox14040454"},{"key":"70855_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2022.113342","volume":"168","author":"BM Bartholomai","year":"2022","unstructured":"Bartholomai, B. M. et al. Safety evaluation of Neurospora crassa mycoprotein for use as a novel meat alternative and enhancer. Food Chem. Toxicol. 168, 113342 (2022).","journal-title":"Food Chem. Toxicol."},{"key":"70855_CR85","doi-asserted-by":"publisher","first-page":"640935","DOI":"10.3389\/fimmu.2021.640935","volume":"12","author":"A Lutterotti","year":"2021","unstructured":"Lutterotti, A., Hayward-Koennecke, H., Sospedra, M. & Martin, R. Antigen-specific immune tolerance in multiple sclerosis-promising approaches and how to bring them to patients. Front. Immunol. 12, 640935 (2021).","journal-title":"Front. Immunol."},{"key":"70855_CR86","doi-asserted-by":"crossref","unstructured":"Rendell, V., Bath, N. M. & Brennan, T. V. Medawar\u2019s paradox and immune mechanisms of fetomaternal tolerance. OBM Transplant. 4, 26 (2020).","DOI":"10.21926\/obm.transplant.2001104"},{"key":"70855_CR87","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41551-019-0431-2","volume":"3","author":"AM Moreno","year":"2019","unstructured":"Moreno, A. M. et al. Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy. Nat. Biomed. Eng. 3, 806\u2013816 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"70855_CR88","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41589-021-00792-9","volume":"17","author":"L He","year":"2021","unstructured":"He, L. et al. Circularly permuted LOV2 as a modular photoswitch for optogenetic engineering. Nat. Chem. Biol. 17, 915\u2013923 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"70855_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-022-00305-2","volume":"26","author":"J Choi","year":"2022","unstructured":"Choi, J. et al. Implantable micro-scale LED device guided photodynamic therapy to potentiate antitumor immunity with mild visible light. Biomater. Res. 26, 56 (2022).","journal-title":"Biomater. Res."},{"key":"70855_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41377-023-01348-3","volume":"13","author":"X Zhong","year":"2024","unstructured":"Zhong, X. et al. Free-moving-state microscopic imaging of cerebral oxygenation and hemodynamics with a photoacoustic fiberscope. Light Sci. Appl. 13, 5 (2024).","journal-title":"Light Sci. Appl."},{"key":"70855_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35259-5","volume":"13","author":"Y Liang","year":"2022","unstructured":"Liang, Y. et al. Optical-resolution functional gastrointestinal photoacoustic endoscopy based on optical heterodyne detection of ultrasound. Nat. Commun. 13, 7604 (2022).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70855-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70855-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70855-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:02:32Z","timestamp":1778760152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70855-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70855"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70855-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Wang is scientific co-founder and consultant of Cell E&G Inc. and Acoustic Cell Therapy Inc. These financial interests do not affect the design, conduct or reporting of this research. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4252"}}